Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: Direct and indirect treatment comparison meta-analysis

Clinical Infectious Diseases

Volumn 52, Issue 3, 2011, Pages 313-321

  Kalil, Andre C ^a   Mindru, Cezarina ^b   Florescu, Diana F ^a  

^a Infectious Diseases Division   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CD3 ANTIBODY; CYCLOSPORIN; GANCICLOVIR; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; META ANALYSIS; NEUTROPENIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; MIDDLE AGED; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79951822463     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq143     Document Type: Article

References (38)

1. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80. (Pubitemid 46202222)
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14. (Pubitemid 350294226)
3. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidencebased reassessment of safety and efficacy. PLoS One 2009;4: e5512.
4. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811-5.
5. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transpl 2004;4:611-20. (Pubitemid 38523584)
6. Valcyte (valganciclovir HCL tablets) dear healthcare professional letter sep 2003 (letter from roche pharmaceuticals). [homepage on the Internet] Accessed at August 17, 2010 Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm169502.htm. Accessed 17 August 2010.
7. Abate MT, Triolo D, Nord EP. CMV infection in renal transplant recipients: Five year experience with campath-1H induction and early steroid withdrawal. Am J Transpl 2009;9:680.
8. Weng FL, Patel AM, Wanchoo R, et al. Oral ganciclovir versus lowdose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007;83:290-6.
9. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007;83:874-82. (Pubitemid 46682727)
10. Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transpl Proc 2004;36:3107-12. (Pubitemid 41126753)
11. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in african-american renal allograft recipients based on donor/recipient serostatus. Clin Transpl 2005;19:273-8. (Pubitemid 40424902)
12. Manuel O, Venetz JP, Fellay J, et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly 2007;137:669-76. (Pubitemid 350221801)
13. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of lowdose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006;12:112-6.
14. Avidan YP, Paul M, Rahamimov R, et al. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. J Infect 2008;57:236-40.
15. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009;20:2449-58.
16. Dupuis R, Harris M, Gillis K, et al. Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients. Transpl Proc 2007;39:3266-70. (Pubitemid 350251506)
17. Brady RL, Green K, Frei C, Maxwell P. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009;11:106-11.
18. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004;24:1323-30. (Pubitemid 39304996)
19. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transpl 2003;3:731-5. (Pubitemid 36745246)
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
21. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91. (Pubitemid 27341818)
22. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
23. Mulrow CD, Cook D. Systematic reviews: synthesis of best evidence for health care decisions. Philadelphia, Pennsylvania: the American College of Physicians, 1998:117.
24. Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
26. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transpl 2005;5:1462-8. (Pubitemid 40839439)
27. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transpl 2006;6:2134-43. (Pubitemid 44199547)
28. Said T, Nampoory MR, Pacsa AS, et al. Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. Transpl Proc 2007;39:997-9. (Pubitemid 46764885)
29. Guirado L, Rabella N, Diaz JM, et al. Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir. Nefrologia 2008;28:293-300.
30. Moro JA, Almenar L, Martinez-Dolz L, et al. Utility of oral valganciclovir for cytomegalovirus prophylaxis: Does it improve treatment compliance? Transpl Proc 2008;40:3063-4.
31. Fernandez A, Amezquita Y, Fernandez-Tagarro E, et al. Prophylaxis and treatment of cytomegalovirus infection postrenal transplantation in two madrid units. Transpl Proc 2009;41:2416-8.
32. Monforte V, Lopez C, Santos F, et al. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Am J Transpl 2009;9:1134-41.
33. Parreira L, Bruges M, Gaspar A, Weigert A, Machado D. Prevention of cytomegalovirus disease in renal transplantation: single-center experience. Transpl Proc 2009;41:877-9.
34. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transpl 2009;28:461-7.
35. Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 2009;15:963-7.
36. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transpl 2004;4:1635-42. (Pubitemid 39312297)
37. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005;40:704-8. (Pubitemid 40381344)
38. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirusresistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004;189:1615-8. (Pubitemid 38648289)